Piper Sandler raises target for Viatris stock to USD 14.00
Alpha Vantage · ad-hoc-news.de · · AI-summarised by FinFlash
Piper Sandler has increased its price target for Viatris stock from USD 13.00 to USD 14.00 following Viatris's agreement to acquire Pacira BioSciences for USD 1.65 billion. This acquisition adds established non-opioid pain treatments and is expected to be immediately accretive to Viatris's financial guidance. Viatris is scheduled to release its third-quarter 2026 results on November 5, 2026.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.